NF1 Cutaneous Neurofibroma Consortium Project (NF1-CNC Project)

  • Research type

    Research Study

  • Full title

    The Neurofibromatosis Type 1 (NF1) Cutaneous Neurofibroma Consortium Project- Identifying genetic modifiers of disease burden to inform treatment pathway - UK addendum.

  • IRAS ID

    311500

  • Contact name

    Emma Burkitt-Wright

  • Contact email

    Emma.Burkitt-Wright@mft.nhs.uk

  • Sponsor organisation

    Manchester University NHS Foundation Trust

  • Duration of Study in the UK

    2 years, 1 months, 0 days

  • Research summary

    Neurofibromatosis type 1 (NF1) is the most common neurogenetic condition. Adult patients report cosmetic disfigurement due to distressing fleshy skin tumours, known as neurofibromas, as the greatest burden of living with NF1. There is currently no way to predict tumour severity which can range from <100 to thousands. This study will conduct a large genome-wide association study within a cohort of 2000 adults with NF1 to identify genetic modifiers to understand disease variability and characterise potential treatment pathways.

    The study is part of an international consortium, the methodology mentioned in the IRAS form is what will be happening in the UK.

  • REC name

    North West - Greater Manchester Central Research Ethics Committee

  • REC reference

    24/NW/0176

  • Date of REC Opinion

    5 Jul 2024

  • REC opinion

    Further Information Favourable Opinion